Collegium Provides 2025 Financial Guidance and Business Update
Portfolio Pulse from
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced its 2025 financial guidance, projecting product revenues between $735 million and $750 million, with Jornay PM® net revenue expected to exceed $135 million. Adjusted EBITDA is anticipated to be between $435 million and $450 million, while adjusted operating expenses are expected to range from $220 million to $230 million.
January 08, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical has provided optimistic 2025 financial guidance, with expected product revenues up to $750 million and Jornay PM® net revenue over $135 million. Adjusted EBITDA is projected to be strong, indicating potential growth.
The announcement of strong financial guidance for 2025, including high revenue expectations and solid EBITDA projections, suggests a positive outlook for Collegium Pharmaceutical. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100